Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:mercuribenzoic acid
go back to main search page
Accession:CHEBI:25194 term browser browse the term
Synonyms:related_synonym: mercuribenzoic acids
 xref: DrugBank:DB03975

show annotations for term's descendants           Sort by:
 
p-chloromercuribenzoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb6 ATP binding cassette subfamily B member 6 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ABCB6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ABCC4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ABCG2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621 		JBrowse link
G Abhd14a abhydrolase domain containing 14A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:115,141,575...115,151,222
Ensembl chr 8:115,141,539...115,149,527 		JBrowse link
G Abhd3 abhydrolase domain containing 3, phospholipase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ABHD3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:1,892,413...1,946,840
Ensembl chr18:1,892,413...1,946,840 		JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of ACAD11 mRNA CTD PMID:26272509 NCBI chr 8:112,594,758...112,676,275
Ensembl chr 8:112,594,691...112,676,280 		JBrowse link
G Acadsb acyl-CoA dehydrogenase, short/branched chain multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACADSB mRNA CTD PMID:27188386 NCBI chr 1:201,981,362...202,022,771
Ensembl chr 1:201,981,357...202,021,008 		JBrowse link
G Acta1 actin, alpha 1, skeletal muscle increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ACTA1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084 		JBrowse link
G Actc1 actin, alpha, cardiac muscle 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ACTC1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939 		JBrowse link
G Adam28 ADAM metallopeptidase domain 28 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ADAM28 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:50,356,745...50,425,911
Ensembl chr15:50,358,192...50,425,900 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ADAMTS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974 		JBrowse link
G Adamts20 ADAM metallopeptidase with thrombospondin type 1 motif, 20 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of ADAMTS20 mRNA CTD PMID:26272509 NCBI chr 7:135,465,021...135,630,941
Ensembl chr 7:135,466,884...135,630,654 		JBrowse link
G Adcyap1r1 ADCYAP receptor type I decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ADCYAP1R1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696 		JBrowse link
G Adgrg2 adhesion G protein-coupled receptor G2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ADGRG2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:36,930,186...37,054,968
Ensembl chr  X:36,930,186...37,003,642 		JBrowse link
G Ajap1 adherens junctions associated protein 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of AJAP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:170,615,885...170,679,315
Ensembl chr 5:170,615,886...170,679,315 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of AKR1C2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of AKR1C3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021 		JBrowse link
G Aldoc aldolase, fructose-bisphosphate C decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ALDOC mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDOC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126 		JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of AMBP mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990 		JBrowse link
G Ank1 ankyrin 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ANK1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:73,681,422...73,912,605
Ensembl chr16:73,681,422...73,827,488 		JBrowse link
G Ankrd1 ankyrin repeat domain 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ANKRD1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548 		JBrowse link
G Ankrd26 ankyrin repeat domain 26 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ANKRD26 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD26 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:150,548,656...150,616,928
Ensembl chr 4:150,547,467...150,616,895 		JBrowse link
G Ankrd37 ankyrin repeat domain 37 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA CTD PMID:27188386 NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888 		JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ANTXR1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:118,946,267...119,131,202
Ensembl chr 4:118,946,268...119,131,202 		JBrowse link
G Anxa1 annexin A1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ANXA1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012 		JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ANXA2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594 		JBrowse link
G Anxa3 annexin A3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ANXA3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437 		JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of AOX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870 		JBrowse link
G Apcdd1 APC down-regulated 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of APCDD1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:58,270,398...58,300,982
Ensembl chr18:58,270,410...58,301,002 		JBrowse link
G Apela apelin receptor early endogenous ligand decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of APELA mRNA CTD PMID:26272509 NCBI chr16:26,582,103...26,583,828 JBrowse link
G Apoa2 apolipoprotein A2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA CTD PMID:27188386 NCBI chr13:89,596,872...89,598,805
Ensembl chr13:89,597,138...89,598,802 		JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ARAP2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:48,726,033...48,922,809
Ensembl chr14:48,726,045...48,922,983 		JBrowse link
G Arf1 ADP-ribosylation factor 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ARF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029 		JBrowse link
G Arhgap15 Rho GTPase activating protein 15 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of ARHGAP15 mRNA CTD PMID:26272509 NCBI chr 3:28,626,987...29,236,225
Ensembl chr 3:28,627,084...29,236,219 		JBrowse link
G Arhgef28 Rho guanine nucleotide exchange factor 28 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ARHGEF28 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF28 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:25,738,514...26,011,429
Ensembl chr 2:25,738,514...26,011,429 		JBrowse link
G Arhgef40 Rho guanine nucleotide exchange factor 40 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ARHGEF40 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF40 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:28,377,916...28,403,090
Ensembl chr15:28,377,996...28,403,090 		JBrowse link
G Arhgef9 Cdc42 guanine nucleotide exchange factor 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ARHGEF9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:64,249,576...64,428,444
Ensembl chr  X:64,248,278...64,428,592 		JBrowse link
G Arl10 ADP-ribosylation factor like GTPase 10 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ARL10 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:10,567,064...10,575,518
Ensembl chr17:10,568,959...10,575,203 		JBrowse link
G Arl9 ADP-ribosylation factor like GTPase 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ARL9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:33,436,803...33,447,516
Ensembl chr14:33,436,980...33,444,235 		JBrowse link
G Armh1 armadillo-like helical domain containing 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ARMH1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARMH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:136,073,056...136,112,344
Ensembl chr 5:136,073,056...136,112,344 		JBrowse link
G Armh4 armadillo-like helical domain containing 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ARMH4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:26,586,359...26,687,412
Ensembl chr15:26,587,179...26,678,420 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of ARRB1 mRNA CTD PMID:26272509 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139 		JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ARX mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:62,363,757...62,376,139
Ensembl chr  X:62,363,757...62,376,143 		JBrowse link
G Asf1a anti-silencing function 1A histone chaperone increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ASF1A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:34,894,419...34,909,265
Ensembl chr20:34,894,419...34,909,265 		JBrowse link
G Asic1 acid sensing ion channel subunit 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ASIC1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ASNS mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163 		JBrowse link
G Asphd1 aspartate beta-hydroxylase domain containing 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ASPHD1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,379,060...198,382,982
Ensembl chr 1:198,379,022...198,382,614 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA CTD PMID:27188386 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632 		JBrowse link
G Atf5 activating transcription factor 5 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ATF5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522 		JBrowse link
G Atg10 autophagy related 10 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ATG10 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATG10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:19,853,546...20,152,918
Ensembl chr 2:19,853,546...20,152,884 		JBrowse link
G Atl3 atlastin GTPase 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ATL3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:222,746,023...222,788,439
Ensembl chr 1:222,746,023...222,786,942 		JBrowse link
G Atp8a1 ATPase phospholipid transporting 8A1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ATP8A1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:41,972,398...42,210,555
Ensembl chr14:42,015,347...42,206,311 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354 		JBrowse link
G Atxn2l ataxin 2-like multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATXN2L mRNA CTD PMID:27188386 NCBI chr 1:197,908,087...197,920,400
Ensembl chr 1:197,908,094...197,919,560 		JBrowse link
G Aurka aurora kinase A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of AURKA mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AURKA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210 		JBrowse link
G B9d1 B9 domain containing 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of B9D1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:47,784,294...47,794,399
Ensembl chr10:47,785,033...47,792,590
Ensembl chr10:47,785,033...47,792,590 		JBrowse link
G Bag2 BAG cochaperone 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BAG2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:38,456,487...38,467,120
Ensembl chr 9:38,456,468...38,467,118 		JBrowse link
G Bag3 BAG cochaperone 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BAG3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191 		JBrowse link
G Bag5 BAG cochaperone 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of BAG5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAG5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:136,180,640...136,185,651
Ensembl chr 6:136,182,006...136,185,651 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BAMBI mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992 		JBrowse link
G Bcan brevican increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of BCAN mRNA CTD PMID:27188386 NCBI chr 2:187,359,674...187,373,133
Ensembl chr 2:187,359,677...187,372,657 		JBrowse link
G Bche butyrylcholinesterase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of BCHE mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCHE mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395 		JBrowse link
G Bcl2l11 BCL2 like 11 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of BCL2L11 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192 		JBrowse link
G Bcl6 BCL6, transcription repressor increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BCL6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075 		JBrowse link
G Bco1 beta-carotene oxygenase 1 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of BCO1 mRNA CTD PMID:26272509 NCBI chr19:49,637,059...49,673,577
Ensembl chr19:49,637,016...49,673,808 		JBrowse link
G Bcor BCL6 co-repressor decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of BCOR mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCOR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:11,570,155...11,692,022
Ensembl chr  X:11,648,989...11,691,099 		JBrowse link
G Bend4 BEN domain containing 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of BEND4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:42,399,359...42,401,643
NCBI chr14:42,401,665...42,437,957
Ensembl chr14:42,401,706...42,431,480 		JBrowse link
G Bend6 BEN domain containing 6 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BEND6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:38,297,253...38,351,312
Ensembl chr 9:38,297,322...38,351,024 		JBrowse link
G Best4 bestrophin 4 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA CTD PMID:27188386 NCBI chr 5:136,013,978...136,017,742
Ensembl chr 5:136,014,017...136,017,677 		JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319 		JBrowse link
G Bik BCL2-interacting killer increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BIK mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447 		JBrowse link
G Bloc1s5 biogenesis of lysosomal organelles complex 1 subunit 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MUTED mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLOC1S5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:26,808,193...26,833,257
Ensembl chr17:26,808,330...26,833,247 		JBrowse link
G Blvrb biliverdin reductase B increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BLVRB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BLVRB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075 		JBrowse link
G Bmp5 bone morphogenetic protein 5 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BMP5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273 		JBrowse link
G Bmp6 bone morphogenetic protein 6 multiple interactions
increases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA
p-Chloromercuribenzoic Acid results in increased expression of BMP6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820 		JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BTG2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982 		JBrowse link
G Btg3 BTG anti-proliferation factor 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of BTG3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:16,873,642...16,889,100
Ensembl chr11:16,873,646...16,889,201 		JBrowse link
G C1s complement C1s increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of C1S mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609 		JBrowse link
G Ca13 carbonic anhydrase 13 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CA13 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:88,282,961...88,314,254
Ensembl chr 2:88,282,961...88,314,254 		JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CA4 mRNA CTD PMID:26272509 NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067 		JBrowse link
G Cabyr calcium binding tyrosine phosphorylation regulated increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CABYR mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CABYR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:4,082,175...4,096,650
Ensembl chr18:4,084,228...4,095,936 		JBrowse link
G Cachd1 cache domain containing 1 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CACHD1 mRNA CTD PMID:26272509 NCBI chr 5:119,596,726...119,832,326
Ensembl chr 5:119,727,839...119,831,634 		JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CACNB2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682 		JBrowse link
G Calb1 calbindin 1 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of CALB1 mRNA CTD PMID:26272509 NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773 		JBrowse link
G Caln1 calneuron 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CALN1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:29,307,117...29,796,996
Ensembl chr12:29,308,341...29,743,705 		JBrowse link
G Camk2d calcium/calmodulin-dependent protein kinase II delta increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CAMK2D mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:230,900,907...231,132,207
Ensembl chr 2:230,901,126...231,132,039 		JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CAMK2N1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:156,876,706...156,878,486
Ensembl chr 5:156,876,706...156,878,486 		JBrowse link
G Capn6 calpain 6 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CAPN6 mRNA CTD PMID:26272509 NCBI chr  X:115,049,113...115,073,824
Ensembl chr  X:115,049,154...115,073,890 		JBrowse link
G Caps2 calcyphosine 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CAPS2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAPS2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:54,858,841...54,917,406
Ensembl chr 7:54,859,104...54,917,323 		JBrowse link
G Cars cysteinyl-tRNA synthetase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CARS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656 		JBrowse link
G Casp3 caspase 3 decreases activity ISO p-Chloromercuribenzoic Acid results in decreased activity of CASP3 protein CTD PMID:26272509 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204 		JBrowse link
G Casp8 caspase 8 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CASP8 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106 		JBrowse link
G Cav2 caveolin 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CAV2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638 		JBrowse link
G Cbx5 chromobox 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CBX5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:144,819,673...144,865,014
Ensembl chr 7:144,819,420...144,837,583 		JBrowse link
G Cc2d1b coiled-coil and C2 domain containing 1B increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CC2D1B mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:128,215,711...128,229,762
Ensembl chr 5:128,215,711...128,229,737 		JBrowse link
G Ccbe1 collagen and calcium binding EGF domains 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CCBE1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:61,758,754...62,013,194
Ensembl chr18:61,759,289...61,788,863 		JBrowse link
G Ccdc121 coiled-coil domain containing 121 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CCDC121 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC121 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:99,819,380...99,821,055
Ensembl chr13:99,820,015...99,820,986 		JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:56,674,737...56,704,501
Ensembl chr 4:56,674,832...56,704,549 		JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:104,403,617...104,410,991
Ensembl chr 6:104,406,897...104,409,005 		JBrowse link
G Ccdc74a coiled-coil domain containing 74A decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CCDC74A mRNA CTD PMID:26272509 NCBI chr11:87,547,026...87,554,513
Ensembl chr11:87,549,059...87,553,336 		JBrowse link
G Ccn1 cellular communication network factor 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA CTD PMID:27188386 NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312 		JBrowse link
G Ccn2 cellular communication network factor 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CCN2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773 		JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068 		JBrowse link
G Ccnt2 cyclin T2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:44,475,959...44,516,892
Ensembl chr13:44,475,970...44,515,739 		JBrowse link
G Cd82 Cd82 molecule decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CD82 mRNA CTD PMID:26272509 NCBI chr 3:82,324,344...82,368,846
Ensembl chr 3:82,324,354...82,368,357 		JBrowse link
G Cdc14b cell division cycle 14B multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA CTD PMID:27188386 NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750 		JBrowse link
G Cdc42bpa CDC42 binding protein kinase alpha increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CDC42BPA mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42BPA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762 		JBrowse link
G Cdh1 cadherin 1 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of CDH1 mRNA CTD PMID:26272509 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395 		JBrowse link
G Cdh11 cadherin 11 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CDH11 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:2,391,181...2,551,245
Ensembl chr19:2,393,059...2,551,245 		JBrowse link
G Cdh6 cadherin 6 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CDH6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:63,100,723...63,246,618
Ensembl chr 2:63,101,739...63,166,509 		JBrowse link
G Cdh7 cadherin 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CDH7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:31,081,064...31,228,884
Ensembl chr13:31,081,804...31,231,213 		JBrowse link
G Cdh9 cadherin 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CDH9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:66,938,796...67,078,897
Ensembl chr 2:66,940,057...67,078,784 		JBrowse link
G Cdk15 cyclin-dependent kinase 15 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CDK15 mRNA CTD PMID:27188386 NCBI chr 9:66,059,765...66,153,729
Ensembl chr 9:66,058,047...66,148,087 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CDK6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CDKN1A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CEBPB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910 		JBrowse link
G Cel carboxyl ester lipase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CEL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522 		JBrowse link
G Celf5 CUGBP, Elav-like family member 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CELF5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:11,095,449...11,119,941
Ensembl chr 7:11,095,468...11,119,941 		JBrowse link
G Cep19 centrosomal protein 19 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP19 mRNA CTD PMID:27188386 NCBI chr11:71,921,713...71,938,335
Ensembl chr11:71,921,716...71,938,165 		JBrowse link
G Cep83 centrosomal protein 83 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CEP83 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP83 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:35,739,553...35,847,618
Ensembl chr 7:35,773,928...35,847,617 		JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CEP85L mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:34,574,043...34,743,142
Ensembl chr20:34,575,950...34,684,418 		JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:64,975,499...65,019,169
Ensembl chr11:64,975,594...65,018,108 		JBrowse link
G Cftr CF transmembrane conductance regulator increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CFTR mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA CTD PMID:27188386 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425 		JBrowse link
G Chd9 chromodomain helicase DNA binding protein 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CHD9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:17,364,969...17,517,757
Ensembl chr19:17,366,828...17,494,585 		JBrowse link
G Chka choline kinase alpha increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CHKA mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:219,076,618...219,126,221
Ensembl chr 1:219,077,771...219,126,220 		JBrowse link
G Chodl chondrolectin increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CHODL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:17,537,980...17,560,305
Ensembl chr11:17,538,063...17,560,296 		JBrowse link
G Chordc1 cysteine and histidine rich domain containing 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA CTD PMID:27188386 NCBI chr 8:17,421,552...17,445,513
Ensembl chr 8:17,421,557...17,446,165 		JBrowse link
G Chrdl1 chordin-like 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CHRDL1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:114,554,359...114,658,975
Ensembl chr  X:114,554,359...114,658,931 		JBrowse link
G Cib1 calcium and integrin binding 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CIB1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:142,014,962...142,020,461
Ensembl chr 1:142,014,958...142,020,525 		JBrowse link
G Cln3 CLN3 lysosomal/endosomal transmembrane protein, battenin increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CLN3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:197,986,384...197,999,726
Ensembl chr 1:197,986,385...197,997,664 		JBrowse link
G Clu clusterin increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CLU mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857 		JBrowse link
G Cluap1 clusterin associated protein 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLUAP1 mRNA CTD PMID:27188386 NCBI chr10:11,847,058...11,878,792
Ensembl chr10:11,847,102...11,878,792 		JBrowse link
G Cnfn cornifelin decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CNFN mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:82,234,032...82,236,602
Ensembl chr 1:82,234,032...82,236,179 		JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:39,711,001...39,953,860
Ensembl chr  X:39,711,201...39,951,847 		JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:49,280,913...49,314,061
Ensembl chr13:49,285,310...49,313,940 		JBrowse link
G Cntnap3 contactin associated protein family member 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CNTNAP3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:2,197,355...2,380,727 JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of COL1A2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151 		JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:69,797,558...69,902,916
Ensembl chr13:69,797,880...69,901,170 		JBrowse link
G Cpeb2 cytoplasmic polyadenylation element binding protein 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CPEB2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:72,327,929...72,382,519
Ensembl chr14:72,331,705...72,380,330 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CPT1A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678 		JBrowse link
G Crem cAMP responsive element modulator increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of CREM mRNA CTD PMID:27188386 NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888 		JBrowse link
G Ctc1 CST telomere replication complex component 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CTC1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:55,596,172...55,616,873
Ensembl chr10:55,596,148...55,616,889 		JBrowse link
G Ctcfl CCCTC-binding factor like multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTCFL mRNA CTD PMID:27188386 NCBI chr 3:171,145,203...171,168,375
Ensembl chr 3:171,145,584...171,166,454 		JBrowse link
G Ctdsp1 CTD small phosphatase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CTDSP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:81,672,613...81,677,979
Ensembl chr 9:81,672,758...81,677,979 		JBrowse link
G Cth cystathionine gamma-lyase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CTH mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046 		JBrowse link
G Ctnnd2 catenin delta 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315 		JBrowse link
G Cuzd1 CUB and zona pellucida-like domains 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUZD1 mRNA CTD PMID:27188386 NCBI chr 1:201,881,846...201,894,970
Ensembl chr 1:201,881,836...201,894,775 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of CXCL12 mRNA CTD PMID:26272509 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891 		JBrowse link
G Cxcl6 C-X-C motif chemokine ligand 6 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CXCL6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCL6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407 		JBrowse link
G Cxcr2 C-X-C motif chemokine receptor 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CXCR2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCR2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of CXCR4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases activity EXP p-Chloromercuribenzoic Acid results in decreased activity of CYP7A1 protein CTD PMID:1175606 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431 		JBrowse link
G Cyth3 cytohesin 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of CYTH3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:12,877,559...12,907,771
Ensembl chr12:12,877,559...12,945,192 		JBrowse link
G Dab1 DAB adaptor protein 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DAB1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115 		JBrowse link
G Dbr1 debranching RNA lariats 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DBR1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DBR1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:107,826,690...107,838,186
Ensembl chr 8:107,826,424...107,838,339 		JBrowse link
G Dcx doublecortin decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DCX mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:115,098,675...115,175,515
Ensembl chr  X:115,098,675...115,175,299 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DDIT3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084 		JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DDIT4L mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:242,882,219...242,885,088
Ensembl chr 2:242,882,306...242,885,131 		JBrowse link
G Ddr2 discoidin domain receptor tyrosine kinase 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DDR2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:88,311,639...88,436,561
Ensembl chr13:88,317,145...88,436,789 		JBrowse link
G Ddx58 DEXD/H-box helicase 58 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DDX58 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX58 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772 		JBrowse link
G Dennd1b DENN domain containing 1B decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DENND1B mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:56,015,813...56,242,041
Ensembl chr13:56,015,901...56,236,677 		JBrowse link
G Dennd2c DENN domain containing 2C increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DENND2C mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND2C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:205,592,348...205,660,619
Ensembl chr 2:205,592,182...205,660,611 		JBrowse link
G Dgki diacylglycerol kinase, iota decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DGKI mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:64,365,115...64,831,473
Ensembl chr 4:64,374,342...64,831,473 		JBrowse link
G Dgkq diacylglycerol kinase, theta decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DGKQ mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKQ mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:2,069,409...2,083,370
Ensembl chr14:2,069,409...2,083,370 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DHRS11 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:72,144,042...72,153,496
Ensembl chr10:72,144,042...72,153,375 		JBrowse link
G Dhrs2 dehydrogenase/reductase 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DHRS2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539 		JBrowse link
G Dhx30 DExH-box helicase 30 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DHX30 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX30 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:118,160,315...118,194,674
Ensembl chr 8:118,160,299...118,187,791 		JBrowse link
G Dio3os DIO3 opposite strand upstream RNA decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DIO3OS mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIO3OS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:134,623,450...134,626,974 JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DLG1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLG1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895 		JBrowse link
G Dll1 delta like canonical Notch ligand 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DLL1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379 		JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DLX3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:82,937,971...82,943,367
Ensembl chr10:82,937,971...82,943,348 		JBrowse link
G Dlx5 distal-less homeobox 5 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DLX5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,387,741...32,392,085
Ensembl chr 4:32,387,741...32,392,007 		JBrowse link
G Dlx6 distal-less homeobox 6 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DLX6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,373,096...32,377,388
Ensembl chr 4:32,373,641...32,377,253 		JBrowse link
G Dnah1 dynein, axonemal, heavy chain 1 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of DNAH1 mRNA CTD PMID:27188386 NCBI chr16:7,345,131...7,407,009
Ensembl chr16:7,345,978...7,408,265 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA CTD PMID:27188386 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919 		JBrowse link
G Dock6 dedicator of cytokinesis 6 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DOCK6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:22,822,412...22,874,670
Ensembl chr 8:22,822,412...22,874,645 		JBrowse link
G Dock7 dedicator of cytokinesis 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of DOCK7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:117,595,194...117,780,844
Ensembl chr 5:117,596,136...117,780,777 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA CTD PMID:27188386 NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418 		JBrowse link
G Dusp10 dual specificity phosphatase 10 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA CTD PMID:27188386 NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455 		JBrowse link
G Dusp14 dual specificity phosphatase 14 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DUSP14 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602 		JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of DUSP5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595 		JBrowse link
G Dusp8 dual specificity phosphatase 8 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA CTD PMID:27188386 NCBI chr 1:215,030,429...215,043,111
Ensembl chr 1:215,030,429...215,033,460 		JBrowse link
G Ebf1 EBF transcription factor 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EBF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EBF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:23,654,849...24,051,627
Ensembl chr10:23,661,013...24,050,209 		JBrowse link
G Eef1akmt2 EEF1A lysine methyltransferase 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EEF1AKMT2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:204,830,008...204,855,627
Ensembl chr 1:204,831,540...204,855,627 		JBrowse link
G Eef1akmt3 EEF1A lysine methyltransferase 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EEF1AKMT3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,320,845...70,328,452
Ensembl chr 7:70,321,077...70,328,148 		JBrowse link
G Efcab6 EF-hand calcium binding domain 6 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB6 mRNA CTD PMID:27188386 NCBI chr 7:124,758,376...124,948,428
Ensembl chr 7:124,758,378...124,929,025 		JBrowse link
G Efhb EF hand domain family, member B increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of EFHB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFHB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:47,988...120,800
Ensembl chr 9:47,724...120,799 		JBrowse link
G Efna1 ephrin A1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of EFNA1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222 		JBrowse link
G Egf epidermal growth factor multiple interactions
increases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA
p-Chloromercuribenzoic Acid results in increased expression of EGF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfl7 EGF-like-domain, multiple 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EGFL7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:4,034,759...4,044,280
Ensembl chr 3:4,034,921...4,043,936 		JBrowse link
G Egfr epidermal growth factor receptor decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EGFR mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796 		JBrowse link
G Egr1 early growth response 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR1 mRNA CTD PMID:27188386 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429 		JBrowse link
G Egr2 early growth response 2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR2 mRNA CTD PMID:27188386 NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025 		JBrowse link
G Egr4 early growth response 4 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR4 mRNA CTD PMID:27188386 NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082 		JBrowse link
G Eid2b EP300 interacting inhibitor of differentiation 2B multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID2B mRNA CTD PMID:27188386 NCBI chr 1:85,508,397...85,510,131
Ensembl chr 1:85,509,662...85,510,114 		JBrowse link
G Eid3 EP300 interacting inhibitor of differentiation 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EID3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:26,976,154...26,977,479 JBrowse link
G Eif2ak4 eukaryotic translation initiation factor 2 alpha kinase 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EIF2AK4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF2AK4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:110,159,624...110,245,382
Ensembl chr 3:110,159,708...110,249,217 		JBrowse link
G Eif3e eukaryotic translation initiation factor 3 subunit E decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of EIF3E mRNA CTD PMID:26272509 NCBI chr 7:82,997,694...83,037,231 JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:132,068,581...132,111,092
Ensembl chr 4:132,068,598...132,111,079 		JBrowse link
G Eno3 enolase 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ENO3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:57,278,271...57,283,661
Ensembl chr10:57,278,307...57,283,653 		JBrowse link
G Epcam epithelial cell adhesion molecule increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of EPCAM mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216 		JBrowse link
G Epdr1 ependymin related 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of EPDR1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:47,397,558...47,422,183
Ensembl chr17:47,397,558...47,422,182 		JBrowse link
G Epha2 Eph receptor A2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA CTD PMID:27188386 NCBI chr 5:159,845,773...159,874,203
Ensembl chr 5:159,845,774...159,874,206 		JBrowse link
G Ephb1 Eph receptor B1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EPHB1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:110,376,954...110,813,193
Ensembl chr 8:110,376,954...110,813,000 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456 		JBrowse link
G Ephx2 epoxide hydrolase 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EPHX2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHX2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ERAP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733 		JBrowse link
G Erich1 glutamate-rich 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ERICH1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:80,601,873...80,667,774
Ensembl chr16:80,601,973...80,667,781 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ERP27 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:170,893,946...170,912,629
Ensembl chr 4:170,893,946...170,912,629 		JBrowse link
G Etaa1 ETAA1 activator of ATR kinase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ETAA1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETAA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:102,290,655...102,293,674
Ensembl chr14:102,290,418...102,293,677 		JBrowse link
G Exoc7 exocyst complex component 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of EXOC7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:105,242,152...105,259,795
Ensembl chr10:105,242,152...105,259,795 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of F2RL2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533 		JBrowse link
G F5 coagulation factor V increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of F5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:82,479,997...82,535,540
Ensembl chr13:82,479,998...82,535,534 		JBrowse link
G Fabp6 fatty acid binding protein 6 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FABP6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:29,191,621...29,196,593
Ensembl chr10:29,191,623...29,196,563 		JBrowse link
G Fam110c family with sequence similarity 110, member C increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FAM110C mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:49,968,473...49,974,730
Ensembl chr 6:49,968,473...49,974,728 		JBrowse link
G Fam124a family with sequence similarity 124 member A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FAM124A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:45,711,994...45,780,395
Ensembl chr15:45,712,821...45,780,405 		JBrowse link
G Fam126a family with sequence similarity 126, member A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FAM126A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM126A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:7,661,710...7,770,179
Ensembl chr 4:7,661,558...7,770,232 		JBrowse link
G Fam149a family with sequence similarity 149, member A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FAM149A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:50,049,816...50,105,962
Ensembl chr16:50,049,828...50,107,856 		JBrowse link
G Fam155a family with sequence similarity 155, member A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FAM155A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM155A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:85,528,126...86,053,447 JBrowse link
G Fam169a family with sequence similarity 169, member A increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of FAM169A mRNA CTD PMID:26272509 NCBI chr 2:27,884,748...27,941,069
Ensembl chr 2:27,905,535...27,938,525 		JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FAM219A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM219A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:57,896,824...57,947,569
Ensembl chr 5:57,897,368...57,947,183 		JBrowse link
G Fank1 fibronectin type III and ankyrin repeat domains 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FANK1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:205,842,469...205,954,152
Ensembl chr 1:205,842,489...205,950,371 		JBrowse link
G Farp2 FERM, ARH/RhoGEF and pleckstrin domain protein 2 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of FARP2 mRNA CTD PMID:27188386 NCBI chr 9:100,660,366...100,767,940
Ensembl chr 9:100,660,394...100,767,940 		JBrowse link
G Fat3 FAT atypical cadherin 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FAT3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:14,417,039...15,011,596
Ensembl chr 8:14,417,584...14,880,644 		JBrowse link
G Fbf1 Fas binding factor 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FBF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:104,692,791...104,718,630
Ensembl chr10:104,692,755...104,718,621 		JBrowse link
G Fblim1 filamin binding LIM protein 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FBLIM1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:160,122,466...160,158,921
Ensembl chr 5:160,122,425...160,158,386 		JBrowse link
G Fbxl14 F-box and leucine-rich repeat protein 14 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FBXL14 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:151,986,890...151,990,706 JBrowse link
G Fbxl17 F-box and leucine-rich repeat protein 17 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FBXL17 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:110,515,558...110,936,631
Ensembl chr 9:110,515,558...110,936,631 		JBrowse link
G Fbxo3 F-box protein 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FBXO3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:93,968,827...94,000,863
Ensembl chr 3:93,968,855...94,000,863 		JBrowse link
G Fbxo9 f-box protein 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FBXO9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,388,331...85,413,896
Ensembl chr 8:85,388,333...85,413,484 		JBrowse link
G Fdft1 farnesyl diphosphate farnesyl transferase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FDFT1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FDFT1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302 		JBrowse link
G Fech ferrochelatase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FECH mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192 		JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FEZ1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270 		JBrowse link
G Fezf2 Fez family zinc finger 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FEZF2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:12,825,333...12,831,496
Ensembl chr15:12,827,707...12,831,496 		JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of FGF8 mRNA CTD PMID:26272509 NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831 		JBrowse link
G Fgf9 fibroblast growth factor 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FGF9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316 		JBrowse link
G Fhod3 formin homology 2 domain containing 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FHOD3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:16,650,786...17,332,209
Ensembl chr18:16,650,806...17,332,210 		JBrowse link
G Filip1 filamin A interacting protein 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FILIP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FILIP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:87,257,312...87,453,432
Ensembl chr 8:87,256,264...87,419,564 		JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FJX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:92,288,818...92,290,919
Ensembl chr 3:92,288,818...92,290,919 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOS mRNA CTD PMID:27188386 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FOSL1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066 		JBrowse link
G Fosl2 FOS like 2, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FOSL2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:25,598,936...25,616,995
Ensembl chr 6:25,598,936...25,616,995 		JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FOXC1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:33,947,501...33,951,484
Ensembl chr17:33,947,506...33,951,484 		JBrowse link
G Frmd3 FERM domain containing 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FRMD3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:90,040,495...90,282,327
Ensembl chr 5:90,040,495...90,282,327 		JBrowse link
G Frzb frizzled-related protein decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of FRZB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:67,635,604...67,668,772
Ensembl chr 3:67,635,607...67,668,772 		JBrowse link
G Fth1 ferritin heavy chain 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FTH1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228 		JBrowse link
G Ftl1 ferritin light chain 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FTL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829 		JBrowse link
G Ftx FTX transcript, XIST regulator increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of FTX mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTX mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:74,440,265...74,484,164 JBrowse link
G Fut8 fucosyltransferase 8 multiple interactions
decreases expression
decreases activity		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8 mRNA; Fucose analog inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein]
p-Chloromercuribenzoic Acid results in decreased expression of FUT8 mRNA		 CTD PMID:12770769 PMID:26272509 PMID:27188386 NCBI chr 6:100,305,957...100,537,208
Ensembl chr 6:100,337,226...100,537,224 		JBrowse link
G Fzd10 frizzled class receptor 10 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of FZD10 mRNA CTD PMID:26272509 NCBI chr12:31,757,407...31,760,604
Ensembl chr12:31,757,407...31,760,604 		JBrowse link
G Fzd2 frizzled class receptor 2 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of FZD2 mRNA CTD PMID:26272509 NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057 		JBrowse link
G G3bp1 G3BP stress granule assembly factor 1 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of G3BP1 mRNA CTD PMID:26272509 NCBI chr10:40,812,858...40,846,252
Ensembl chr10:40,812,858...40,846,252 		JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858 		JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:112,833,941...112,947,482
Ensembl chr 1:112,833,944...112,947,451 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GABRB3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GADD45A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA CTD PMID:27188386 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322 		JBrowse link
G Gal galanin and GMAP prepropeptide decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GAL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925 		JBrowse link
G Galnt10 polypeptide N-acetylgalactosaminyltransferase 10 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA CTD PMID:27188386 NCBI chr10:43,067,316...43,208,992
Ensembl chr10:43,067,299...43,210,427 		JBrowse link
G Galnt14 polypeptide N-acetylgalactosaminyltransferase 14 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GALNT14 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:24,770,308...24,985,711
Ensembl chr 6:24,770,317...24,985,716 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GALNT3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:52,174,469...52,212,395
Ensembl chr 3:52,175,547...52,212,412 		JBrowse link
G Galp galanin-like peptide decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of GALP mRNA CTD PMID:26272509 NCBI chr 1:71,352,417...71,374,457
Ensembl chr 1:71,352,419...71,373,605 		JBrowse link
G Gars glycyl-tRNA synthetase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GARS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044 		JBrowse link
G Gas1 growth arrest-specific 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GAS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940 		JBrowse link
G Gata2 GATA binding protein 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GATA2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488 		JBrowse link
G Gata3 GATA binding protein 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GATA3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GCLC mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GCLM mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874 		JBrowse link
G Gcnt1 glucosaminyl (N-acetyl) transferase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GCNT1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:236,547,729...236,585,037
Ensembl chr 1:236,580,034...236,585,035 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GDF15 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978 		JBrowse link
G Gemin8 gem (nuclear organelle) associated protein 8 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GEMIN8 mRNA CTD PMID:27188386 NCBI chr  X:29,806,605...29,825,439
Ensembl chr  X:29,806,606...29,825,439 		JBrowse link
G Gfra1 GDNF family receptor alpha 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GFRA1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:279,203,046...279,572,789 JBrowse link
G Gins4 GINS complex subunit 4 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GINS4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GINS4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:73,584,412...73,596,808
Ensembl chr16:73,584,521...73,596,793 		JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360 		JBrowse link
G Gls glutaminase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GLS mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872 		JBrowse link
G Gng8 G protein subunit gamma 8 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GNG8 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:78,818,360...78,822,224
Ensembl chr 1:78,818,404...78,822,224 		JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GPAT3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:10,343,287...10,396,565
Ensembl chr14:10,343,282...10,395,047 		JBrowse link
G Gpm6b glycoprotein m6b decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GPM6B mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:29,604,607...29,751,174
Ensembl chr  X:29,607,075...29,648,403 		JBrowse link
G Gpnmb glycoprotein nmb increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GPNMB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683 		JBrowse link
G Gpr25 G protein-coupled receptor 25 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of GPR25 mRNA CTD PMID:27188386 NCBI chr13:53,135,815...53,139,180
Ensembl chr13:53,136,174...53,137,253 		JBrowse link
G Gpx1 glutathione peroxidase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GPX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522 		JBrowse link
G Gramd1c GRAM domain containing 1C decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GRAMD1C mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:61,609,370...61,659,355
NCBI chr11:62,580,983...62,634,961
Ensembl chr11:61,605,937...62,634,803 		JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GREM1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989 		JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GRHL3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:153,893,039...153,925,045
Ensembl chr 5:153,893,039...153,924,896 		JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:127,561,843...127,829,763
Ensembl chr  X:127,562,660...127,829,753 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GRIN2A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990 		JBrowse link
G Grm3 glutamate metabotropic receptor 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GRM3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:21,316,761...21,567,561
Ensembl chr 4:21,317,695...21,560,490 		JBrowse link
G Gsr glutathione-disulfide reductase increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of GSR mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361 		JBrowse link
G Gtf2h1 general transcription factor IIH subunit 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GTF2H1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2H1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:102,849,618...102,877,939
Ensembl chr 1:102,849,889...102,877,944 		JBrowse link
G Gucy1a2 guanylate cyclase 1 soluble subunit alpha 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of GUCY1A2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1A2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:408,001...899,851
Ensembl chr 8:408,001...899,974 		JBrowse link
G H1f7 H1.7 linker histone increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of H1-7 mRNA CTD PMID:27188386 NCBI chr 7:139,871,491...139,872,858
Ensembl chr 7:139,871,479...139,872,900 		JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HACD1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:81,173,238...81,196,012
Ensembl chr17:81,173,713...81,187,739 		JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HAPLN1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:18,354,542...18,419,077
Ensembl chr 2:18,354,542...18,419,071 		JBrowse link
G Heg1 heart development protein with EGF-like domains 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HEG1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:70,234,248...70,322,966
Ensembl chr11:70,236,888...70,322,690 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA CTD PMID:27188386 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254 		JBrowse link
G Hes1 hes family bHLH transcription factor 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HES1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248 		JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HES5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:172,364,421...172,365,188
Ensembl chr 5:172,364,421...172,365,188 		JBrowse link
G Hes7 hes family bHLH transcription factor 7 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of HES7 mRNA CTD PMID:27188386 NCBI chr10:55,704,485...55,710,523
Ensembl chr10:55,707,164...55,709,687 		JBrowse link
G Hesx1 HESX homeobox 1 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of HESX1 mRNA CTD PMID:26272509 NCBI chr16:2,616,538...2,636,708
Ensembl chr16:2,634,603...2,636,708 		JBrowse link
G Hif3a hypoxia inducible factor 3 subunit alpha multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA CTD PMID:27188386 NCBI chr 1:78,976,318...78,997,869
Ensembl chr 1:78,976,318...78,997,869 		JBrowse link
G Hist1h2bd histone cluster 1 H2B family member D multiple interactions
decreases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
p-Chloromercuribenzoic Acid results in decreased expression of H2BC5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:44,833,924...44,834,305
Ensembl chr17:44,833,924...44,834,305 		JBrowse link
G Hmbs hydroxymethylbilane synthase increases activity EXP p-chloromercuribenzoic acid increases activity of purified Hmbs protein RGD PMID:3179323 RGD:2301707 NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748 		JBrowse link
G Hmgcll1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA CTD PMID:27188386 NCBI chr 8:83,069,837...83,204,778
Ensembl chr 8:83,070,545...83,205,441 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HMGCS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HMOX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456 		JBrowse link
G Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HNRNPA2B1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPA2B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282 		JBrowse link
G Hnrnpl heterogeneous nuclear ribonucleoprotein L multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPL mRNA CTD PMID:27188386 NCBI chr 1:86,994,090...87,006,776
Ensembl chr 1:86,996,093...87,006,776 		JBrowse link
G Hnrnpu heterogeneous nuclear ribonucleoprotein U increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of HNRNPU mRNA CTD PMID:26272509 NCBI chr13:96,222,093...96,238,845
Ensembl chr13:96,225,912...96,238,572 		JBrowse link
G Hopx HOP homeobox decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HOPX mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOPX mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:33,354,803...33,362,547
Ensembl chr14:33,354,807...33,362,551 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of HPGD mRNA CTD PMID:26272509 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758 		JBrowse link
G Hps3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HPS3 mRNA CTD PMID:27188386 NCBI chr 2:104,789,423...104,832,964
Ensembl chr 2:104,789,423...104,830,898 		JBrowse link
G Hrh3 histamine receptor H3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HRH3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395 		JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HRK mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:44,008,879...44,029,211 JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:50,369,097...50,402,584
Ensembl chr10:50,366,952...50,402,616 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HSD17B8 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235 		JBrowse link
G Hspa12a heat shock protein family A (Hsp70) member 12A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HSPA12A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:279,946,809...280,104,366
Ensembl chr 1:279,946,811...280,015,358 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1A mRNA CTD PMID:27188386 NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779 		JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HSPA1L mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HSPA4L mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503 		JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPD1 mRNA CTD PMID:27188386 NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HSPH1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of HTATIP2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461 		JBrowse link
G Htra1 HtrA serine peptidase 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of HTRA1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,499,067...201,548,508
Ensembl chr 1:201,499,028...201,548,513 		JBrowse link
G Ica1l islet cell autoantigen 1-like increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of ICA1L mRNA CTD PMID:27188386 NCBI chr 9:66,788,094...66,848,958
Ensembl chr 9:66,790,047...66,845,403 		JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ICAM1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059 		JBrowse link
G Ice2 interactor of little elongation complex ELL subunit 2 multiple interactions
decreases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ICE2 mRNA
p-Chloromercuribenzoic Acid results in decreased expression of ICE2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:75,625,147...75,666,959
Ensembl chr 8:75,625,174...75,666,866 		JBrowse link
G Icoslg inducible T-cell co-stimulator ligand increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ICOSLG mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICOSLG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:11,330,000...11,340,307
Ensembl chr20:11,329,992...11,340,296 		JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ID1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718 		JBrowse link
G Ier2 immediate early response 2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER2 mRNA CTD PMID:27188386 NCBI chr19:25,774,146...25,775,670
Ensembl chr19:25,774,143...25,775,659 		JBrowse link
G Ier3 immediate early response 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of IER3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769 		JBrowse link
G Ifrd1 interferon-related developmental regulator 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA CTD PMID:27188386 NCBI chr 6:60,132,025...60,151,354
Ensembl chr 6:60,132,024...60,151,420 		JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of IGDCC3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGDCC3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:70,630,546...70,685,882
Ensembl chr 8:70,630,767...70,684,115 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of IGFBP3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of IGFBP5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033 		JBrowse link
G Igsf5 immunoglobulin superfamily, member 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of IGSF5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:36,736,580...36,779,614
Ensembl chr11:36,736,586...36,779,615 		JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA CTD PMID:27188386 NCBI chr  X:55,439,388...57,004,865
Ensembl chr  X:55,439,578...56,765,893 		JBrowse link
G Il1rn interleukin 1 receptor antagonist increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of IL1RN mRNA CTD PMID:27188386 NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614 		JBrowse link
G Ing3 inhibitor of growth family, member 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ING3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ING3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:49,017,235...49,044,450
Ensembl chr 4:49,017,311...49,042,990 		JBrowse link
G Inhbe inhibin subunit beta E increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of INHBE mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of INPP5D mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:94,745,220...94,850,778
Ensembl chr 9:94,745,217...94,850,771 		JBrowse link
G Insig1 insulin induced gene 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of INSIG1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515 		JBrowse link
G Ireb2 iron responsive element binding protein 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of IREB2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IREB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118 		JBrowse link
G Isl2 ISL LIM homeobox 2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA CTD PMID:27188386 NCBI chr 8:60,117,565...60,122,716
Ensembl chr 8:60,117,729...60,122,211 		JBrowse link
G Itga4 integrin subunit alpha 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ITGA4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:66,178,745...66,265,547
Ensembl chr 3:66,193,059...66,263,960 		JBrowse link
G Itprid2 ITPR interacting domain containing 2 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of ITPRID2 mRNA CTD PMID:27188386 NCBI chr 3:66,593,767...66,631,143
Ensembl chr 3:66,593,934...66,631,723 		JBrowse link
G Jade1 jade family PHD finger 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of JADE1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JADE1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:128,461,147...128,514,298
Ensembl chr 2:128,461,224...128,514,291 		JBrowse link
G Jazf1 JAZF zinc finger 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of JAZF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:82,834,181...83,141,430
Ensembl chr 4:82,836,260...83,137,527 		JBrowse link
G Jdp2 Jun dimerization protein 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of JDP2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:109,464,910...109,505,591
Ensembl chr 6:109,466,060...109,505,161 		JBrowse link
G Jph4 junctophilin 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of JPH4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:33,767,116...33,777,289
Ensembl chr15:33,768,595...33,775,109 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA CTD PMID:27188386 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUNB mRNA CTD PMID:27188386 NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756 		JBrowse link
G Kat14 lysine acetyltransferase 14 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT14 mRNA CTD PMID:27188386 NCBI chr 3:138,508,899...138,549,437
Ensembl chr 3:138,504,214...138,549,437 		JBrowse link
G Kat6a lysine acetyltransferase 6A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KAT6A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:73,942,669...74,020,750
Ensembl chr16:73,943,455...74,023,005 		JBrowse link
G Katnbl1 katanin regulatory subunit B1 like 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KATNBL1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:103,511,653...103,513,498
Ensembl chr 3:103,866,144...103,905,936 		JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070 		JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KCNK10 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:122,417,079...122,549,532
Ensembl chr 6:122,419,046...122,545,899 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KEAP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779 		JBrowse link
G Kif1a kinesin family member 1A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KIF1A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:100,171,851...100,253,626
Ensembl chr 9:100,171,772...100,253,609 		JBrowse link
G Kif5c kinesin family member 5C multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF5C mRNA CTD PMID:27188386 NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407 		JBrowse link
G Kirrel2 kirre like nephrin family adhesion molecule 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KIRREL2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIRREL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:88,909,829...88,921,154
Ensembl chr 1:88,910,415...88,920,291 		JBrowse link
G Klf5 Kruppel-like factor 5 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KLF5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921 		JBrowse link
G Klf9 Kruppel-like factor 9 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KLF9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:240,908,483...240,933,198
Ensembl chr 1:240,908,483...240,933,198 		JBrowse link
G Klhdc8a kelch domain containing 8A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KLHDC8A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:49,074,644...49,082,729
Ensembl chr13:49,074,644...49,082,729 		JBrowse link
G Klhdc9 kelch domain containing 9 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KLHDC9 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:89,742,750...89,746,254
Ensembl chr13:89,742,750...89,745,835 		JBrowse link
G Klhl21 kelch-like family member 21 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA CTD PMID:27188386 NCBI chr 5:169,181,418...169,190,073
Ensembl chr 5:169,181,418...169,190,073 		JBrowse link
G Klhl29 kelch-like family member 29 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KLHL29 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL29 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:29,178,858...29,483,460
Ensembl chr 6:29,178,858...29,483,460 		JBrowse link
G Klhl5 kelch-like family member 5 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA CTD PMID:27188386 NCBI chr14:44,805,213...44,867,075
Ensembl chr14:44,805,200...44,845,218 		JBrowse link
G Kmt2a lysine methyltransferase 2A decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KMT2A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:49,110,407...49,185,872
Ensembl chr 8:49,114,990...49,158,971 		JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of KRAS mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558 		JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KRT18 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131 		JBrowse link
G Krt8 keratin 8 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of KRT8 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803 		JBrowse link
G Layn layilin increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of LAYN mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:55,447,203...55,469,420
Ensembl chr 8:55,447,709...55,467,688 		JBrowse link
G Lfng LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LFNG mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LFNG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:16,117,767...16,126,211
Ensembl chr12:16,118,634...16,126,953 		JBrowse link
G Lhx2 LIM homeobox 2 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of LHX2 mRNA CTD PMID:26272509 NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446 		JBrowse link
G Lhx8 LIM homeobox 8 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of LHX8 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:260,572,205...260,598,744
Ensembl chr 2:260,574,190...260,596,777 		JBrowse link
G Lifr LIF receptor subunit alpha increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of LIFR mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415 		JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LIX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:59,156,021...59,212,878
Ensembl chr 1:59,156,251...59,214,452 		JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of LMAN1 mRNA CTD PMID:26272509 NCBI chr18:61,683,377...61,707,344
Ensembl chr18:61,685,117...61,707,317 		JBrowse link
G Lmf1 lipase maturation factor 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LMF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:14,945,185...15,031,855
Ensembl chr10:14,945,265...15,031,942 		JBrowse link
G Lmln leishmanolysin like peptidase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LMLN mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMLN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:70,895,141...70,963,121
Ensembl chr11:70,897,052...70,961,358 		JBrowse link
G Lmo1 LIM domain only 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LMO1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:173,728,183...173,764,288
Ensembl chr 1:173,728,184...173,764,250 		JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LMO3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:172,942,023...173,005,630
Ensembl chr 4:172,942,020...173,005,634 		JBrowse link
G Lmo7 LIM domain 7 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of LMO7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:86,242,911...86,458,512
Ensembl chr15:86,243,148...86,457,739 		JBrowse link
G Lnx1 ligand of numb-protein X 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of LNX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:36,047,136...36,149,740
Ensembl chr14:36,047,144...36,149,740 		JBrowse link
G LOC100910258 zinc finger protein 599-like decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ZNF599 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF599 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:89,672,308...89,686,143 JBrowse link
G LOC498122 similar to CG15908-PA decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of C22ORF39 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C22ORF39 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:86,299,210...86,303,453
Ensembl chr11:86,299,210...86,303,453 		JBrowse link
G LOC686035 similar to heat shock 70kDa protein 6 (HSP70B) multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA6 mRNA CTD PMID:27188386 NCBI chr13:89,408,703...89,411,500 JBrowse link
G LOC689959 hypothetical protein LOC689959 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr 8:55,164,736...55,174,613
Ensembl chr 8:55,164,736...55,171,718 		JBrowse link
G LOC691113 hypothetical protein LOC691113 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:100,208,612...100,215,824
Ensembl chr 4:100,209,951...100,212,122 		JBrowse link
G Lonrf3 LON peptidase N-terminal domain and ring finger 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of LONRF3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:122,937,987...122,973,289
Ensembl chr  X:122,938,009...122,973,321 		JBrowse link
G Lrrc34 leucine rich repeat containing 34 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LRRC34 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:116,370,013...116,391,964
Ensembl chr 2:116,372,519...116,391,959 		JBrowse link
G Lrrc3b leucine rich repeat containing 3B decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LRRC3B mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:11,221,161...11,299,563
Ensembl chr15:11,298,478...11,299,257 		JBrowse link
G Lrrc55 leucine rich repeat containing 55 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LRRC55 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:72,589,840...72,605,089
Ensembl chr 3:72,589,842...72,602,548 		JBrowse link
G Lrrtm4 leucine rich repeat transmembrane neuronal 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of LRRTM4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRTM4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:110,699,577...111,497,643
Ensembl chr 4:110,699,557...111,497,643 		JBrowse link
G Lurap1 leucine rich adaptor protein 1 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of LURAP1 mRNA CTD PMID:27188386 NCBI chr 5:134,991,997...135,001,720
Ensembl chr 5:134,991,997...135,001,720 		JBrowse link
G Lztfl1 leucine zipper transcription factor-like 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LZTFL1 mRNA CTD PMID:27188386 NCBI chr 8:132,774,393...132,790,922
Ensembl chr 8:132,775,587...132,790,839 		JBrowse link
G Mab21l2 mab-21 like 2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA CTD PMID:27188386 NCBI chr 2:185,849,749...185,852,833
Ensembl chr 2:185,850,232...185,852,759 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MACC1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:147,315,232...147,392,530
Ensembl chr 6:147,315,328...147,394,269 		JBrowse link
G Macroh2a1 macroH2A.1 histone decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:9,282,109...9,344,698
Ensembl chr17:9,282,675...9,344,678 		JBrowse link
G Maf MAF bZIP transcription factor decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of MAF mRNA CTD PMID:26272509 NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA CTD PMID:27188386 NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095 		JBrowse link
G Mafg MAF bZIP transcription factor G increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MAFG mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:35,257,688...35,450,132
Ensembl chr20:35,257,985...35,450,513 		JBrowse link
G Man1c1 mannosidase, alpha, class 1C, member 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MAN1C1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:152,775,031...152,920,130
Ensembl chr 5:152,774,855...152,920,343 		JBrowse link
G Map1a microtubule-associated protein 1A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MAP1A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MAP2K6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287 		JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA CTD PMID:27188386 NCBI chr10:91,303,428...91,353,601
Ensembl chr10:91,303,428...91,353,601 		JBrowse link
G Map6 microtubule-associated protein 6 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MAP6 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:164,225,776...164,292,094
Ensembl chr 1:164,225,934...164,292,093 		JBrowse link
G Map7 microtubule-associated protein 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MAP7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:15,620,665...15,748,203
Ensembl chr 1:15,620,653...15,748,203 		JBrowse link
G Marchf1 membrane associated ring-CH-type finger 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MARCHF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARCHF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:24,998,709...25,856,327
Ensembl chr16:25,001,666...25,192,675 		JBrowse link
G Mars1 methionyl-tRNA synthetase 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARS1 mRNA CTD PMID:27188386 NCBI chr 7:70,585,011...70,602,425
Ensembl chr 7:70,585,013...70,602,310 		JBrowse link
G Marveld3 MARVEL domain containing 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MARVELD3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:41,710,076...41,724,923
Ensembl chr19:41,710,102...41,724,923 		JBrowse link
G Matk megakaryocyte-associated tyrosine kinase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MATK mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MATK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:11,325,246...11,334,311
Ensembl chr 7:11,325,254...11,330,278 		JBrowse link
G Mcc MCC regulator of WNT signaling pathway increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MCC mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:35,683,185...35,817,117
NCBI chr 1:12,006,663...12,128,849
Ensembl chr 1:12,006,660...12,128,845
Ensembl chr18:12,006,660...12,128,845 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MCM7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016 		JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:251,930,532...252,007,722
Ensembl chr 2:251,983,339...252,007,560 		JBrowse link
G Mctp1 multiple C2 and transmembrane domain containing 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MCTP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:3,400,883...4,089,949
Ensembl chr 2:3,400,977...4,088,989 		JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MDM2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328 		JBrowse link
G Me1 malic enzyme 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of ME1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834 		JBrowse link
G Me3 malic enzyme 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of ME3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:153,861,535...154,058,608
Ensembl chr 1:153,861,569...154,056,654 		JBrowse link
G Med24 mediator complex subunit 24 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MED24 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MED24 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:86,620,166...86,658,014
Ensembl chr10:86,620,160...86,645,529 		JBrowse link
G Meiob meiosis specific with OB-fold decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MEIOB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:14,174,645...14,206,026
Ensembl chr10:14,174,732...14,206,025 		JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MEOX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:89,797,011...89,817,009
Ensembl chr10:89,797,038...89,816,491 		JBrowse link
G Mettl7b methyltransferase like 7B increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of METTL7B mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL7B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:3,383,876...3,386,522
Ensembl chr 7:3,383,879...3,386,522 		JBrowse link
G Mfap3l microfibril associated protein 3 like decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:32,734,059...32,777,091
Ensembl chr16:32,738,265...32,753,278 		JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MFNG mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:119,978,981...119,996,824
Ensembl chr 7:119,978,983...119,996,824 		JBrowse link
G Miat myocardial infarction associated transcript increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MIAT mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIAT mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:50,447,251...50,461,859 JBrowse link
G Mical3 microtubule associated monooxygenase, calponin and LIM domain containing 3 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of MICAL3 mRNA CTD PMID:27188386 NCBI chr 4:153,484,876...153,631,986
Ensembl chr 4:153,484,876...153,593,773 		JBrowse link
G Mier3 MIER family member 3 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of MIER3 mRNA CTD PMID:26272509 NCBI chr 2:43,266,301...43,295,175
Ensembl chr 2:43,266,739...43,294,889 		JBrowse link
G Mif4gd MIF4G domain containing decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MIF4GD mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:104,159,170...104,164,166
Ensembl chr10:104,159,173...104,163,634 		JBrowse link
G Mir34a microRNA 34a multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA CTD PMID:27188386 NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592 		JBrowse link
G Mkln1 muskelin 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MKLN1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MKLN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:58,693,384...58,817,924
Ensembl chr 4:58,693,384...58,817,691 		JBrowse link
G Mlxip MLX interacting protein decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of MLXIP mRNA CTD PMID:27188386 NCBI chr12:38,567,438...38,638,952
Ensembl chr12:38,567,247...38,638,536 		JBrowse link
G Mmab metabolism of cobalamin associated B decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MMAB mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:47,920,712...47,935,438
Ensembl chr12:47,920,743...47,935,525 		JBrowse link
G Mnx1 motor neuron and pancreas homeobox 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MNX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:2,376,350...2,381,308
Ensembl chr 4:2,376,958...2,381,271 		JBrowse link
G Mphosph8 M-phase phosphoprotein 8 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPHOSPH8 mRNA CTD PMID:27188386 NCBI chr15:36,918,843...36,946,712
Ensembl chr15:36,918,843...36,946,708 		JBrowse link
G Mpi mannose phosphate isomerase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MPI mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPI mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:62,324,176...62,332,080
Ensembl chr 8:62,324,092...62,332,115 		JBrowse link
G Mpp7 membrane palmitoylated protein 7 decreases expression ISO p-Chloromercuribenzoic Acid results in decreased expression of MPP7 mRNA CTD PMID:27188386 NCBI chr17:60,057,077...60,250,303
Ensembl chr17:60,059,949...60,250,352 		JBrowse link
G Mrps14 mitochondrial ribosomal protein S14 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MRPS14 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MRPS14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:77,940,454...77,946,201
Ensembl chr13:77,940,454...77,946,201 		JBrowse link
G Msrb3 methionine sulfoxide reductase B3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:62,850,506...62,972,487
Ensembl chr 7:62,850,515...62,972,084 		JBrowse link
G Msx1 msh homeobox 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MSX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:77,712,262...77,716,061
Ensembl chr14:77,712,240...77,716,059 		JBrowse link
G Msx2 msh homeobox 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MSX2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:11,683,862...11,689,527
Ensembl chr17:11,683,862...11,689,527 		JBrowse link
G Mt2A metallothionein 2A increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MT2A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740 		JBrowse link
G Mtss1 MTSS I-BAR domain containing 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MTSS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:98,820,799...98,960,878
Ensembl chr 7:98,820,812...98,960,837 		JBrowse link
G Muc15 mucin 15, cell surface associated increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MUC15 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:101,895,363...101,912,979
Ensembl chr 3:101,899,068...101,912,919 		JBrowse link
G Mxd1 max dimerization protein 1 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MXD1 mRNA CTD PMID:27188386 NCBI chr 4:118,451,752...118,472,150
Ensembl chr 4:118,449,882...118,472,179 		JBrowse link
G Mycl MYCL proto-oncogene, bHLH transcription factor decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MYCL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:140,691,947...140,698,837
Ensembl chr 5:140,692,779...140,698,609 		JBrowse link
G Mylip myosin regulatory light chain interacting protein increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of MYLIP mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:19,682,040...19,703,681
Ensembl chr17:19,682,040...19,703,681 		JBrowse link
G Mylk myosin light chain kinase decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of MYLK mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158 		JBrowse link
G Myo10 myosin X multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA CTD PMID:27188386 NCBI chr 2:77,868,398...78,072,443
Ensembl chr 2:77,868,412...78,071,309 		JBrowse link
G Myof myoferlin increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of MYOF mRNA CTD PMID:26272509 NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730 		JBrowse link
G N4bp2l2 NEDD4 binding protein 2-like 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of N4BP2L2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:627,128...650,604
Ensembl chr12:628,488...650,376 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NABP1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:55,049,893...55,057,784
Ensembl chr 9:55,050,203...55,057,658 		JBrowse link
G Nadk2 NAD kinase 2, mitochondrial decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NADK2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:58,462,588...58,504,735
Ensembl chr 2:58,462,588...58,504,728 		JBrowse link
G Nap1l5 nucleosome assembly protein 1-like 5 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NAP1L5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAP1L5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:89,149,314...89,152,511
Ensembl chr 4:89,149,317...89,151,184 		JBrowse link
G Nat1 N-acetyltransferase 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NAT1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573 		JBrowse link
G Natd1 N-acetyltransferase domain containing 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NATD1 mRNA
p-Chloromercuribenzoic Acid results in decreased expression of NATD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:47,154,443...47,164,622
Ensembl chr10:47,157,481...47,164,596 		JBrowse link
G Ncald neurocalcin delta decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NCALD mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:76,199,305...76,632,847
Ensembl chr 7:76,199,306...76,488,216 		JBrowse link
G Ncam1 neural cell adhesion molecule 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NCAM1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358 		JBrowse link
G Ncan neurocan decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NCAN mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:21,050,243...21,076,707
Ensembl chr16:21,050,243...21,076,707 		JBrowse link
G Ncoa7 nuclear receptor coactivator 7 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NCOA7 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:29,225,727...29,386,642
Ensembl chr 1:29,225,707...29,385,199 		JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NDP mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:6,791,090...6,815,586
Ensembl chr  X:6,791,136...6,815,583
Ensembl chr  X:6,791,136...6,815,583 		JBrowse link
G Ndufb1 NADH:ubiquinone oxidoreductase subunit B1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:125,861,219...125,870,231 JBrowse link
G Nebl nebulette increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NEBL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEBL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:84,141,014...84,247,038
Ensembl chr17:84,140,489...84,488,601 		JBrowse link
G Nectin4 nectin cell adhesion molecule 4 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NECTIN4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:89,755,665...89,774,185
Ensembl chr13:89,755,845...89,774,378 		JBrowse link
G Nefm neurofilament medium increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NEFM mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604 		JBrowse link
G Nell2 neural EGFL like 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NELL2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:136,526,497...136,853,820
Ensembl chr 7:136,526,496...136,853,957 		JBrowse link
G Nexmif neurite extension and migration factor decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NEXMIF mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:74,943,440...75,053,559
Ensembl chr  X:74,945,082...74,968,405 		JBrowse link
G Nf1 neurofibromin 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NF1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903 		JBrowse link
G Nfasc neurofascin decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NFASC mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:49,335,407...49,522,474
Ensembl chr13:49,335,408...49,522,415 		JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NFE2L2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996 		JBrowse link
G Nfkbiz NFKB inhibitor zeta increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NFKBIZ mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFKBIZ mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487 		JBrowse link
G Nhlh2 nescient helix loop helix 2 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NHLH2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:204,427,577...204,432,946
Ensembl chr 2:204,427,608...204,432,946 		JBrowse link
G Nhs NHS actin remodeling regulator decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NHS mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:34,312,102...34,675,912
Ensembl chr  X:34,623,405...34,673,742 		JBrowse link
G Nkain3 Sodium/potassium transporting ATPase interacting 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
p-Chloromercuribenzoic Acid results in decreased expression of NKAIN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:34,133,596...34,813,668
Ensembl chr 5:34,174,411...34,813,116 		JBrowse link
G Nmrk1 nicotinamide riboside kinase 1 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NMRK1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:234,721,992...234,749,452
Ensembl chr 1:234,721,974...234,749,447 		JBrowse link
G Nog noggin multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ZBTB47 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACADSB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDOC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD18A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD26 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKRD37 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATG10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AURKA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BAG5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCHE mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCOR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BLOC1S5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BTN3A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C22ORF39 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C4ORF47 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C9ORF72 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CBX5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC121 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP19 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CEP83 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLUAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUZD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCL6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DBR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDIT4L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DDX58 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKQ mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHX30 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIO3OS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLG1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EBF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID2B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF2AK4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ENO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETAA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXOC7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM126A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM155A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FDFT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FILIP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FJX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GEMIN8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLUD2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2H1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCY1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H3C10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DOA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOPX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HPS3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ICE2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGDCC3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ING3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IREB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JADE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIRREL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF3-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL29 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LFNG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00648 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00664 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC00960 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01006 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01138 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMLN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRTM4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LZTFL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARCHF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MATK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ME3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MED24 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR124-2HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIR210HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MKLN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MRPS14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NADK2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAP1L5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NATD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPHP4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPTX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP160 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP62CL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OBSL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ODF3B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OSCP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAPLN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PARP16 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAXIP1-DT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PBX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCBP4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH18 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCDH8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PCSK9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDCD4-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDZD2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PFKFB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PHF20L1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PKNOX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU3F2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU4F1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPIL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R16A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP1R1C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PPP2R2B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRIMA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKCB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PSMB8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTGS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTRH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PXK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PYGO1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB40B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RABGAP1L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAI2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of REPS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RET mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFLNB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RFX4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGMB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RIPPLY3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RMST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RND2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF125 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RORB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSBN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSPO3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RUNDC3B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SALL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMD13 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SAMHD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCN7A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCUBE2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEC24B-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SELENOW mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEPTIN6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SERPINB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SETD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEZ6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SFRP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SKIDA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A23 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC25A43 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC2A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC39A10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC3A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC4A8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLITRK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMARCE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMIM14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMKR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNAP23 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOBP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX2-OT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPIN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPIRE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SPON1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SQLE mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SREBF2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SSX2IP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STAMBP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STK32A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of STOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SULF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SUV39H2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYNCRIP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYT9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TAF9B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCEAL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TCF25 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TEKT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TFDP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TINCR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TKFC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM107 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM108 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM132D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM178A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM231 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM35A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM74 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMTC4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNFRSF19 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOB1-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOLLIP-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPBG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRAPPC11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRMT1L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRPC4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSC2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTC30A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TTYH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TWIST2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2J1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ULK2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UPK1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VCAM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WIBG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WIF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WNT5B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of WSCD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of XPNPEP3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZDHHC2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFP14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFPM2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZFR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZHX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF174 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF214 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF287 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF382 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF436-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF521 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF599 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF704 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN12 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZSCAN31 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD36B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARF1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGEF40 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARMH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATXN2L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BIK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BLVRB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CABYR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAPS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42BPA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COPG2IT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTCFL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND2C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLGAP1-AS2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFCAB6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFHB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGR4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM219A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTX mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GINS4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GOLGA8H mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GUSBP4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERC5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPA2B1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNRNPL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA12A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA1L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICOSLG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUNB mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF25-AS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF5C mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC-PINT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00304 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01234 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of METTL7B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIAT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR570HG mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPHOSPH8 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1E mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1F mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1G mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1H mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1HL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1M mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1X mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MXD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEBL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFKBIZ mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLRP7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOL3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NXPE3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PALLD mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PANX2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDHB7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PELO mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PERP mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIR mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLK2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PMAIP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R15A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSMA5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSMD11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSME4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PSPH mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PVT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PWWP2B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PXDC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB17 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB20 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBM47 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RDH12 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of REV3L mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RGS7 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPRM mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A14 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAMD4A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SBF2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCARNA17 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN8A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERTAD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SESN2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFXN5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGPP2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHC1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHTN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC10A4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC13A4 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC22A15 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC30A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35G2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC6A16 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A11 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A5 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQSTM1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SRXN1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STC2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STEAP1B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STK17A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STS mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STX3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STYK1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1A2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYNE1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SYT2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDO2 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TES mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TEX19 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFE3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THBS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD7A mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THUMPD3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TKT mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM144 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM268 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM37 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFRSF10D mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF9 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPP1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPTE2P6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TREX1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIB3 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRIM73 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRO mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSGA10 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TWIST1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TXNL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TXNRD1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UCHL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UNKL mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP43 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEGFA mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGF mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VGLL1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT6 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWTR1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of XIST mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of YARS1 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZDHHC13 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36 mRNA; [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNF750 mRNA CTD PMID:27188386 NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386 		JBrowse link
G Nol3 nucleolar protein 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NOL3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOL3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:37,232,567...37,236,668
Ensembl chr19:37,235,001...37,236,649 		JBrowse link
G Nol4 nucleolar protein 4 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA CTD PMID:27188386 NCBI chr18:13,658,260...14,016,713
Ensembl chr18:13,658,271...14,016,713 		JBrowse link
G Nos2 nitric oxide synthase 2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NOS2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190 		JBrowse link
G Nphp4 nephrocystin 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NPHP4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPHP4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:169,647,581...169,744,662
Ensembl chr 5:169,659,188...169,744,660 		JBrowse link
G Nppb natriuretic peptide B increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of NPPB mRNA CTD PMID:26272509 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531 		JBrowse link
G Nptx1 neuronal pentraxin 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NPTX1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPTX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:108,682,637...108,691,592
Ensembl chr10:108,682,638...108,691,367 		JBrowse link
G Npy2r neuropeptide Y receptor Y2 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NPY2R mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:181,528,949...181,538,145
Ensembl chr 2:181,530,832...181,531,978 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA
p-Chloromercuribenzoic Acid results in increased expression of NQO1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180 		JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NR2F1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894 		JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 multiple interactions ISO [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NR2F2 mRNA CTD PMID:27188386 NCBI chr 1:131,447,671...131,465,749
Ensembl chr 1:131,448,447...131,460,473 		JBrowse link
G Nrip3 nuclear receptor interacting protein 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NRIP3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRIP3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:174,385,424...174,411,141
Ensembl chr 1:174,385,424...174,411,141 		JBrowse link
G Nrxn3 neurexin 3 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NRXN3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:112,133,204...114,069,589
Ensembl chr 6:112,133,204...114,067,564 		JBrowse link
G Nsl1 NSL1 component of MIS12 kinetochore complex decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NSL1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NSL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:109,669,646...109,697,849
Ensembl chr13:109,669,680...109,696,918 		JBrowse link
G Nsun6 NOP2/Sun RNA methyltransferase 6 increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of NSUN6 mRNA CTD PMID:26272509 NCBI chr17:82,020,316...82,060,533
Ensembl chr17:82,022,490...82,060,123 		JBrowse link
G Ntn4 netrin 4 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NTN4 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NTN4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:34,533,543...34,649,330
Ensembl chr 7:34,533,543...34,649,481 		JBrowse link
G Nup160 nucleoporin 160 decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NUP160 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP160 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:79,496,239...79,562,163
Ensembl chr 3:79,498,179...79,551,128 		JBrowse link
G Nup62cl nucleoporin 62 C-terminal like decreases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in decreased expression of NUP62CL mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUP62CL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:111,333,274...111,390,023
Ensembl chr  X:111,334,252...111,365,849 		JBrowse link
G Nutm2f NUT family member 2F increases expression ISO p-Chloromercuribenzoic Acid results in increased expression of NUTM2B mRNA CTD PMID:27188386 NCBI chr17:15,022,052...15,031,768
Ensembl chr17:15,022,951...15,030,364 		JBrowse link
G Nxpe3 neurexophilin and PC-esterase domain family, member 3 increases expression
multiple interactions		 ISO p-Chloromercuribenzoic Acid results in increased expression of NXPE3 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NXPE3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:47,188,332...47,238,372
Ensembl chr11:47,188,495...47,238,372